Rheumatologist says arthritis patients often mistake methotrexate for chemotherapy

A California rheumatologist is spotlighting a common source of fear for arthritis patients: methotrexate is also used as a cancer drug, but at very different doses. Dr. Nisha Manek says clearer explanation can reduce panic, improve trust and help patients understand that rheumatology treats inflammation, not pain alone.

Why it matters: - Methotrexate is a core medication in rheumatology and a familiar cancer therapy at much higher doses, which can make newly diagnosed arthritis patients panic when they look up their prescription. - Dr. Nisha Manek says the confusion is common, avoidable and tied to how little time patients usually get to process a new diagnosis.

What happened: - Dr. Nisha Manek, a rheumatologist who spent 12 years at Mayo Clinic in Rochester, Minnesota, said patients with rheumatoid arthritis often go home, search methotrexate and find it described as a cancer drug. - Manek said patients frequently react with fear before anyone explains the dose difference or the reason the drug is being used. - The article was issued from Yorba Linda, California, on Oct. 9, 2026.

The details: - Manek said methotrexate is used worldwide as a foundation medication in rheumatology. - Manek said the same medication is also used intravenously at very high doses to kill cancer cells. - In rheumatology, Manek said, the doses are much smaller and the drug works by regulating the immune response rather than attacking cancer. - Manek said patients often notice the word cancer immediately and many later say nobody had ever explained the difference to them. - Manek said the typical 10-minute visit leaves little time to address what a patient may have read online late at night. - Manek said many patients tell her they feel invisible, have not been examined in years, or do not feel known by the clinicians treating them. - Manek said rheumatology is an immune-system specialty, not a pain-management specialty, and that pain often improves once inflammation is treated. - Manek left Mayo Clinic in 2012 to study energy medicine and consciousness research from a physics perspective. - Manek is the author of "Bridging Science and Spirit" and works with a small number of clients with chronic inflammatory conditions. - The release cites a 2003 paper by Manek and co-authors on body mass index and knee osteoarthritis. - For more information, the release directs readers to the doctor’s website. - The release also lists Manek's social profiles on LinkedIn, Instagram, Facebook, YouTube and Rumble.

Between the lines: - The release frames patient fear as a communication problem as much as a medical one. - Manek’s message suggests that better counseling at the point of prescribing could reduce anxiety and improve adherence. - The emphasis on feeling invisible points to a broader trust gap between some chronic-disease patients and their care teams.

What's next: - Manek says the practical fix is more time and clearer explanation when methotrexate is prescribed. - The article points readers to Manek’s website for additional information and contact details. - Manek’s work with chronic inflammatory clients and her authorship suggest she may continue speaking on the overlap between medicine, communication and patient experience.